Drug Database
Back to search

Ireland· IE-PA-EU/1/23/1745/001

Tyruko 300 mg concentrate for solution for infusion

A natalizumab product containing natalizumab, registered in Ireland by Polpharma Biologics S.A.. The same ATC class is registered in 2 of our 19 countries.

ATC L04AA23

Checked against HPRA (Ireland) on

Informational only — not a medical device.

SOURCE REGISTER · IEHPRA (Ireland)normalisedTyruko 300 mg concentrate for solutio…ATCL04AA23REGISTER NO.IE-PA-EU/1/23/1745/001PACKS LISTED1CHECKEDSeptember 28, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about natalizumabAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Natalizumab is registered in 2 of 19 countries.

Countries holding a registration under ATC L04AA23 (natalizumab), each read from that country’s own register.

  • This record: Ireland, from HPRA (Ireland)
  • 1 of them publish a price we can compare per daily dose
Search natalizumab products by name

Natalizumab · ATC L04AA23

2 / 19 countries

  • Ireland
  • Polandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

HPRA (Ireland)
Active substance
Natalizumab
Manufacturer
Polpharma Biologics S.A.
Country
Ireland (IE)
ATC code
L04AA23
ATC class
Natalizumab
Reimbursed
Not published by this register
Source register
HPRA (Ireland)
Last checked
September 28, 2026

Packs & prices · 1

  • ie_pa_number
    EU/1/23/1745/001

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

323 interactions on record for natalizumab.

Graded by severity as the source publishes them — 301 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check natalizumab against other medicinesHow interaction checks work

Natalizumab · interactions on record

323 records

  • 301 severe
  • 15 moderate
  • 7 minor

Most severe, free to view

  • PrednisoloneA07EA01severe
  • HydrocortisoneA07EA02severe
  • PrednisoneA07EA03severe
  • BetamethasoneA07EA04severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Natalizumab in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All natalizumab products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Tyruko, Tysabri
  • Liechtenstein · Tyruko, Tysabri
  • Norway · Tyruko, Tysabri

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/5ab36925-d589-4b4b-9232-bcdbf875cbe1
GET /v1/drugs/5ab36925-d589-4b4b-9232-bcdbf875cbe1?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Concentrate for solution for infusion",
  "routes": [
    "Intravenous use"
  ],
  "source": "hpra",
  "atc_all": [
    "L04AA23"
  ],
  "strength": null,
  "pa_number": "EU/1/23/1745/001",
  "substances": [
    "Natalizumab"
  ],
  "legal_basis": "Similar biological application (Article 10(4) of Directive No 2001/83/EC)",
  "market_info": "Unknown",
  "authorised_at": "22/09/2023",
  "dispensing_status": "Product subject to prescription which may not be renewed (A)",
  "registration_status": "AU",
  "supply_legal_status": "Supply through pharmacies only",
  "interchangeable_code": null
}
API referenceMCP serverPlans

See everything about natalizumab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console